DEXCOM INC 10-Q

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Purchases of Equity Securities by the Issuer On July 28, 2022, we announced that a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023 (the “Share Repurchase Program”). The Share Repurchase Program and the remaining authorization of approximately $142.3 million expired on June 30, 2023. There were no share repurchases under the Share Repurchase Program for the three months ended June 30, 2023. The following table provides information about purchases by the Company of its shares of common stock during the three months ended June 30, 2023: Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced program Maximum dollar value of shares that may yet to be purchased under the program (in millions) 4/1/2023 - 4/30/2023 — $ — — $ 142.3 5/1/2023 - 5/31/2023 1,597,500 (1) $ 118.12 (1) — $ 142.3 6/1/2023 - 6/30/2023 — $ — — $ 142.3 (1) In May 2023, we used a portion of the proceeds of the 2028 Notes to repurchase 1.6 million shares of our common stock for $188.7 million for an average per share price of $118.12, via privately negotiated transactions, independent of the Share Repurchase Program. See Note 5, “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for information about the 2028 Notes. See Note 8, “Stockholders’ Equity” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for information about the Share Repurchase Program. ITEM 3 - DEFAULTS UPON SENIOR SECURITIES None. ITEM 4 - MINE SAFETY DISCLOSURES None.